The use of biologic therapy in pregnancy: A gastroenterologist's perspective

Current Opinion in Rheumatology

Volumn 26, Issue 3, 2014, Pages 347-353

  Hassid, Benjamin ^a   Mahadevan, Uma ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

adalimumab; breastfeeding; certolizumab pegol; inflammatory bowel disease; infliximab; pregnancy

Indexed keywords

ALLOPURINOL; AMINOSALICYLIC ACID; CORTICOSTEROID; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ADALIMUMAB; AMINOSALICYLIC ACID DERIVATIVE; BIOLOGICAL PRODUCT; GLUCOCORTICOID; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADVERSE OUTCOME; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; BREAST FEEDING; CONGENITAL DISORDER; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG SAFETY; FETUS OUTCOME; FOOD AND DRUG ADMINISTRATION; GASTROENTEROLOGIST; HIGH RISK PREGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLAMMATORY BOWEL DISEASE; LACTATION; LOW BIRTH WEIGHT; NONHUMAN; OBSTETRIC PATIENT; PANCREATITIS; PATIENT CARE; PATIENT SAFETY; PLACENTAL TRANSFER; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; RISK; SPONTANEOUS ABORTION; ANTAGONISTS AND INHIBITORS; FEMALE; INFLAMMATORY BOWEL DISEASES; PREGNANCY COMPLICATIONS;

AMINOSALICYLIC ACIDS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; FEMALE; GLUCOCORTICOIDS; HUMANS; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897498133     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000048     Document Type: Review

References (51)

1. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101:1274-1282.
2. Selinger CP, Eaden J, Selby W, et al. Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views. J Crohns Colitis 2013; 7:e206-e213.
3. Gawron LM, Hammond C, Keefer L. Documentation of reproductive health counseling and contraception in women with inflammatory bowel diseases. Patient Educ Couns 2014; 94:134-137.
4. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis 2009; 15:1399-1409.
5. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007; 56:830-837.
6. Nguyen GC, Boudreau H, Harris ML, Maxwell CV. Outcomes of obstetric hospitalizations among women with inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2009; 7:329-334.
7. Riis L, Vind I, Politi P, et al. Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101:1539-1545.
8. Stephansson O, Larsson H, Pedersen L, et al. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2011; 17:795-801.
9. Norgard B, Fonager K, Sorensen HT, Olsen J. Birth outcomes of women with ulcerative colitis: a nationwide Danish cohort study. Am J Gastroenterol 2000; 95:3165-3170.
10. Waljee A, Waljee J, Morris AM, Higgins PD. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut 2006; 55:1575-1580.
11. Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38:460-466.
12. Sheibani S, Mahadevan U. Management of biologic agents during pregnancy in patients with inflammatory bowel disease. Pract Gastroenterol 2013; 37:34-39.
13. Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 2008; 103:1203-1209.
14. Biedermann L, Rogler G, Vavricka SR, et al. Pregnancy and breastfeeding in inflammatory bowel disease. Digestion 2012; 86 (Suppl. 1):45-54.
15. Gallinger ZR, Nguyen GC. Presence of phthalates in gastrointestinal medications: is there a hidden danger? World J Gastroenterol 2013; 19:7042-7047.
16. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008; 25:271-275.
17. Singh A, Martin CF, Kane S, et al. Is Asacol use associated with congenital anomalies? Results from a nationwide prospective pregnancy registry. Digestive Disease Week; 2013; Orlando, Florida.
18. Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther 2012; 35:501-515.
19. Branski D, Kerem E, Gross-Kieselstein E, et al. Bloody diarrhea-a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr 1986; 5:316-317.
20. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385-392.
21. Dotan I, Alper A, Rachmilewitz D, et al. Maternal inflammatory bowel disease has short and long-term effects on the health of their offspring: a multicenter study in Israel. J Crohns Colitis 2013; 7:542-550.
22. Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr 1985; 106:1008-1011.
23. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002; 65:240-261.
24. De Boer NK, Jarbandhan SV, de Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006; 101:1390-1392.
25. Jharap B, de Boer NK, Stokkers P, et al. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2014; 63:451-457.
26. Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108:433-440.
27. Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:15-22.
28. De Meij TG, Jharap B, Kneepkens CM, et al. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 38:38-43.
29. Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Expert Rev Clin Immunol 2013; 9:161-173; quiz 74.
30. Mahadevan U, Martin CF, Sandler RS, et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012; 142 (Suppl. 1):S-149.
31. Christensen LA, Dahlerup JF, Nielsen MJ, et al. Azathioprine treatment during lactation. Aliment Pharmacol Ther 2008; 28:1209-1213.
32. Fazal MW, Doogue MP, Leong RW, et al. Allopurinol use in pregnancy in three women with inflammatory bowel disease: safety and outcomes: a case series. BMC Gastroenterol 2013; 13:172.
33. Johns DG, Rutherford LD, Leighton PC, Vogel CL. Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972; 112:978-980.
34. Hinkes E, Plotkin D. Reversible drug-induced sterility in a patient with acute leukemia. JAMA 1973; 223:1490-1491.
35. Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med 2013; 11:174.
36. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol 2013; 19:2591-2602.
37. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17:1846-1854.
38. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013; 108:1426-1438.
39. Bortlik M, Machkova N, Duricova D, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study. Scand J Gastroenterol 2013; 48:951-958.
40. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11:286-292; quiz e24.
41. Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing antitumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11:318-321.
42. Johnsson A, Avlund S, Grosen A, Julsgaard M. Chicken pox infection in a three months old infant exposed in utero to adalimumab. J Crohns Colitis 2013; 7:e116-e117.
43. Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol 2010; 8:475-476.
44. Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011; 5:555-558.
45. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012; 79:1130-1135.
46. Schneider H, Weber CE, Hellwig K, et al. Natalizumab treatment during pregnancy: effects on the neonatal immune system. Acta Neurol Scand 2013; 127:e1-e4.
47. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367:1519-1528.
48. Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 2012; 11:1240.
49. Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep 2012; 6:105-107.
50. Cather JC, Rahawi KW, Schaufelberger D, et al. Pregnancy outcomes in women exposed to ustekinumab in the psoriasis clinical development program. Clin Dermatol 2013.
51. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012; 367:616-624.